21
Participants
Start Date
February 29, 2012
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
TA-650
TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
Investigational site, Chūbu
Investigational site, Hokkaido
Investigational site, Hokuriku
Investigational site, Kanto
Investigational site, Kinki
Investigational site, Kyusyu
Investigational site, Tōhoku
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
INDUSTRY